Mellati et al. (90) suggested that anti–PD-1, and possibly anti–PDL-1 antibody treatment could be responsible for a quick progression of autoimmune diabetes in human subjects characterized by an elevated underlying genetic predisposition to T1D, similarly to that observed in rodent models. This evidence concerns the gene PDCD1 and type 1 diabetes mellitus.